# Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome

> **NCT01373333** · — · NO_LONGER_AVAILABLE · sponsor: **The Cleveland Clinic**

## Conditions studied

- Lambert-Eaton Myasthenic Syndrome

## Interventions

- **DRUG:** 3,4 DAP

## Key facts

- **NCT ID:** NCT01373333
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** 1997-09
- **Primary completion:** 2012-09
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2016-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01373333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01373333, "Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01373333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*